TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03912272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training
Description: In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Control
Description: In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
Study: NCT04024137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 200 mg
Description: 1 X 200-mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets taken orally
Study: NCT02226341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144
Study: NCT04024137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273-400 mg
Description: 2 X 200-mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 tablet taken orally
Study: NCT02226341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTHar gel
Description: Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTHar gel
Description: Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
Study: NCT00376961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 on day 1 for cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
Study: NCT04024137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273-600 mg
Description: 3 X 200-mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of ZSP1273
Study: NCT02214810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Exparel
Description: The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Exparel
Description: The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
Study: NCT03698461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: * 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)
Study: NCT00376961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 on day 1 of cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2 on day 1 of cycles 1-6.
Study: NCT03698461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
Study: NCT00376961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on days 1-5 of cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2 on day 1 of cycles 1-6.
Study: NCT05237557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative nurse dialogue
Description: Performance of a preoperative nurse dialogue prior major visceral surgery
Study: NCT04920409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAWGT diet
Description: Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet (UD)
Description: Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
Study: NCT03698461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: * 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)
Study: NCT02213133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (KPT-330)
Description: Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (KPT-330)
Description: Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
Study: NCT00618722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01925989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered SQ

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SQ
Study: NCT02842905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitting Audiologist completion
Description: Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Physician completion
Description: Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
Study: NCT03726996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Study drug (desipramine) provided in tablet form to be taken daily.
Study: NCT02012582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: i.v. infusion
Study: NCT02243384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hepatectomy
Description: A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
Study: NCT02012582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. infusion
Study: NCT04964193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elzsa film-coated tablet
Description: Administered with 240 mL of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane-35 Sugar-coated tablet
Description: Administered with 240 mL of water
Study: NCT03513081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educative session
Description: The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
Study: NCT00511225

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 10,000 IU weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study: NCT00865423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg Tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 800 mg Tablets, single dose
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study: NCT01676038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pinless-Navigated Total Knee Arthroplasty
Description: Brainlab VectorVision Knee 2.5 Navigation System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Knee Arthroplasty
Description: Conventional technique.
Study: NCT04387292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam
Description: * Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)
Study: NCT00482963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel, efavirenz
Study: NCT03551548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: 25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Study: NCT01136551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
Study: NCT01401569

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and counseling (for smoking cessation and physical activity)
Description: Exercise and counseling (for smoking cessation and physical activity)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and counseling (for smoking cessation and physical activity)
Description: Exercise and counseling (for smoking cessation and physical activity)
Study: NCT02312024

Intervention type: DEVICE
Intervention: Use of CytoSorb adsorber
Description: Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.

Intervention type: DEVICE
Intervention: Use of CytoSorb adsorber
Description: Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
Study: NCT04239846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-701 Topical Gel 0.3%
Description: AC-701 Topical Gel 0.3%, BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel, BID
Study: NCT03700411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Perioperative epidural analgesia
Study: NCT02692547

Intervention type: DEVICE
Group type: OTHER
Intervention: Hybrid-logic closed loop system
Description: All patients get to wear the pump
Study: NCT02684071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra thecal methotrexate
Description: IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: To be administered in conjunction with methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: To be administered in conjunction with methotrexate and topotecan
Study: NCT00820326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolasetron
Description: Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
Study: NCT01417676

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: pelvic lymph nodes with boost to prostate
Description: 78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
Study: NCT01332708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high complex carbohydrates diet given in a diet group
Description: diet groups that meet every week for eight weeks or more.
Study: NCT00709826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine: per package insert.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine: per package insert.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 100 mg tablets, 400 mg/day
Study: NCT04428489

Intervention type: OTHER
Intervention: Observation and necessary supportive care
Description: For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
Study: NCT00709826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib - per package insert.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib - per package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib
Description: apricoxib: 100mg tablets, given orally
Study: NCT04172090

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Normal physical activity and standard energy intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT+E
Description: Reduced physical activity and standard energy intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT=E
Description: Reduced physical activity and reduced energy intake
Study: NCT03631927

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT03856957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff colonoscopy
Description: Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: colonoscopy without endocuff
Study: NCT03065179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: IV immunotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be delivered in conjunction with immunotherapy
Study: NCT03502512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery with REVOLVE technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery with PureGraft technique
Study: NCT04159090

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-PSMA
Description: Patients with moderate or high risk of prostate cancer
Study: NCT03294993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound assess
Description: The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
Study: NCT01973257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: imaging diagnostics
Study: NCT04222829

Intervention type: PROCEDURE
Intervention: Megadose Shinbaro Pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases.
Study: NCT02850848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entigin Film Coated Tablet 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Baraclude 0.5mg Tablets
Study: NCT04023084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
Study: NCT00138216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT00138216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT02115386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: supplied in 150 mg capsules to be taken orally
Study: NCT00138216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02979756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decentralized GDM screening and initial management
Description: Screening for GDM and initialization of nutritional therapy at the first level of care
Study: NCT00623831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixed bacterial vaccine
Description: MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixed bacterial vaccine
Description: MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
Study: NCT01800721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SNAP
Description: Behavioral: SNAP 7 group sessions, and 1 individual session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SNAP Control
Description: Behavioral: SNAP control 7 group sessions